Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Randox unveils new non-invasive test for early detection of colorectal cancer

Randox Laboratories : 23 October, 2007  (New Product)
Randox Laboratories has developed a new patient friendly test for the detection of mutations associated with colorectal cancer.
The test allows the analysis of DNA in stool samples without the need for dietary or medication changes.

As many as 90 percent of colorectal cancers can be cured if caught at an early stage. Early diagnosis is essential for improvement of patient prognosis in colorectal cancer and screening programmes have already been implemented throughout Europe utilising Faecal Occult Blood tests (FOBt), where positive FOBts are followed by colonoscopy. However, although FOB testing is non-invasive and inexpensive, it suffers from low sensitivity and specificity and results in up to 50 percent of colonoscopies being performed on patients unnecessarily.

Low patient compliance for colonoscopy and the requirement of a surgeon to perform the procedure mean that an intermediate test method for the detection of colorectal cancer would be beneficial.

Chromosomal instability accounts for 85 percent of sporadic colorectal cancers. The ability to screen for point mutations from this pathway using the Randox test in a patient presenting with a positive FOBt provides a valuable aid to the screening process by offering a highly specific test that may also benefit from increased patient compliance.

The DNA array from Randox allows the detection of 28 mutations associated with the chromosomal instability pathway. The new test will increase early detection of both cancer and precancerous lesions and reduce the incidence of mortality associated with colorectal cancer.

Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo